Amgen Inc. (AMGN) Position Cut by First Citizens Bank & Trust Co.
First Citizens Bank & Trust Co. lowered its position in Amgen Inc. (NASDAQ:AMGN) by 19.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 62,649 shares of the medical research company’s stock after selling 14,863 shares during the period. First Citizens Bank & Trust Co.’s holdings in Amgen were worth $9,532,000 at the end of the most recent quarter.
Other institutional investors also recently added to or reduced their stakes in the company. Oakworth Capital Inc. raised its stake in Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Delta Asset Management LLC TN raised its stake in Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC raised its stake in Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Vigilant Capital Management LLC raised its stake in Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares in the last quarter. Finally, Calamos Wealth Management LLC acquired a new stake in Amgen during the second quarter worth $202,000. 79.12% of the stock is currently owned by institutional investors.
Amgen Inc. (NASDAQ:AMGN) traded up 0.11% during mid-day trading on Tuesday, hitting $162.80. 2,001,839 shares of the stock were exchanged. The company has a 50-day moving average of $169.07 and a 200-day moving average of $162.61. The stock has a market capitalization of $121.83 billion, a PE ratio of 16.66 and a beta of 0.94. Amgen Inc. has a 52 week low of $139.02 and a 52 week high of $176.85.
Amgen (NASDAQ:AMGN) last announced its earnings results on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, beating the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The business earned $5.69 billion during the quarter, compared to analysts’ expectations of $5.58 billion. During the same period in the prior year, the company earned $2.57 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. On average, equities analysts predict that Amgen Inc. will post $11.35 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Shareholders of record on Wednesday, November 16th will be issued a dividend of $1.00 per share. The ex-dividend date of this dividend is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a yield of 2.46%. Amgen’s dividend payout ratio is currently 40.90%.
A number of equities research analysts recently weighed in on AMGN shares. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $166.35 target price on the stock. in a report on Monday, August 1st. Goldman Sachs Group Inc. reiterated a “buy” rating and issued a $204.00 price objective on shares of Amgen in a research note on Thursday, September 8th. Cowen and Company reiterated a “buy” rating on shares of Amgen in a research note on Monday, September 19th. Jefferies Group reiterated a “buy” rating and issued a $187.00 price objective on shares of Amgen in a research note on Wednesday, July 13th. Finally, Piper Jaffray Cos. reiterated a “buy” rating and issued a $193.00 price objective on shares of Amgen in a research note on Thursday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company’s stock. Amgen presently has an average rating of “Buy” and an average target price of $184.94.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.